-
公开(公告)号：WO2008127271A3
公开(公告)日：2009-04-09
申请号：PCT/US2007019660
申请日：2007-09-07
Applicant: ABBOTT LAB , WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
Abstract translation: 本发明包括IL-13结合蛋白。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-13具有高亲和力，并在体外和体内中和hIL-13活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-13和抑制hIL-13活性，例如在患有hTL-13活性有害的病症的人类受试者中。
-
公开(公告)号：EP2064336A4
公开(公告)日：2010-03-17
申请号：EP07873427
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
CPC classification number: A61K45/06 , A61K38/00 , A61K39/3955 , C07K14/47 , C07K16/244 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：ZA200901526B
公开(公告)日：2018-11-28
申请号：ZA200901526
申请日：2009-03-03
Applicant: ABBOTT LAB
Inventor： MELIM TERRY L , CUFF CAROLYN A , ARGIRIADI MARIA A , WU CHENGBIN , HINTON PAUL R , DIXON RICHARD W , KUMAR SHANKAR , BELK JONATHAN P , CHEN YAN , YING HUANG
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：CA2662701C
公开(公告)日：2015-12-08
申请号：CA2662701
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
IPC: C07K16/24 , A61K39/395 , A61K47/48 , A61K49/00 , A61K51/10 , C07K16/46 , C12N15/13 , C12N15/63 , C12P21/08
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
-
公开(公告)号：DOP2009000033A
公开(公告)日：2009-03-15
申请号：DO2009000033
申请日：2009-03-04
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Abstract: Proteínas de unión a !L-13. Específicamente, la invención se relaciona con anticuerpos que son quiméricos, con injertos de CDR y anticuerpos humanizados. Los anticuerpos preferidos tienen gran afinidad por la hIL-13 y neutralizan la actividad de la hIL-13 in vitro e in vivo. Un anticuerpo de la invención puede ser un anticuerpo de longitud completa o una porción de unión al antigeno del mismo. Tambien se provee un método de elaboración y un método de uso de los anticuerpos de la invención. Los anticuerpos, o porciones de anticuerpo, de la invención son de utilidad para detectar la hIL-13 y para inhibir la actividad hIL-13, por ejemplo, en un sujeto humano que sufre de un trastorno en el cual la actividad de la hIL-13 sea perjudicial.
-
Patent Agency Ranking
公开(公告)号：SG174782A1
公开(公告)日：2011-10-28
申请号：SG2011064268
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, SDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hTL-13 activity is detrimental.
-
公开(公告)号：CA2662701A1
公开(公告)日：2008-10-23
申请号：CA2662701
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： KUMAR SHANKAR , HINTON PAUL R , WU CHENGBIN , CUFF CAROLYN A , MELIM TERRY L , DIXON RICHARD W , BELK JONATHAN P , CHEN YAN , ARGIRIADI MARIA A , YING HUA
Abstract: The present invention encompasses IL- 13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and human ized antibodies. Preferred antibodies have high affinity for hIL-13 and neut ralize hIL-13 activity in vitro and in vivo. An antibody of the invention ca n be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provide d. The antibodies, or antibody portions, of the invention are useful for det ecting hIL-13 and for inhibiting hlL-13 activity, e.g., in a human subject s uffering from a disorder in which hTL-13 activity is detrimental.
-
公开(公告)号：NZ599144A
公开(公告)日：2013-10-25
申请号：NZ59914407
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： WU CHENGBIN , DIXON RICHARD W , BELK JONATHAN P , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , HINTON PAUL R , KUMAR SHANKAR , MELIM TERRY L , CHEN YAN
Abstract: 599144 Disclosed is a binding protein that possesses an antigen binding domain, said binding protein capable of binding IL-13, said antigen binding domain comprising six CDRs: CDR-H1 (TSDMGVD), CDR-H2 (HIWWDDVKRYNPALKS), CDR-H3 (TVSSGYIYYAMDY), CDR-L1 (RASQDIRNYLN), CDR-L2 (YTSKLHS or YTSMKPR), and CDR-L3 (QQGNTLPLT or QQGLTPPLT).
-
公开(公告)号：NO20091411L
公开(公告)日：2009-05-22
申请号：NO20091411
申请日：2009-04-07
Applicant: ABBOTT LAB
Inventor： HINTON PAUL R , BELK JONATHAN P , DIXON RICHARD W , KUMAR SHANKAR , WU CHENGBIN , YING HUA , ARGIRIADI MARIA A , CUFF CAROLYN A , MELIM TERRY L , CHEN YAN
Abstract: The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.
-
公开(公告)号：MX2009002554A
公开(公告)日：2009-03-20
申请号：MX2009002554
申请日：2007-09-07
Applicant: ABBOTT LAB
Inventor： HINTON PAUL R , DIXON RICHARD W , BELK JONATHAN P , KUMAR SHANKAR , WU CHENGBIN , ARGIRIADI MARIA A , YING HUA , CUFF CAROLYN A , MELIM TERRY L , CHEN YAN
Abstract: La presente invención comprende proteínas de enlace lL 13. Específicamente la presente invención se refiere a anticuerpos que son anticuerpos quiméricos, injertados con CDR y humanizados. Los anticuerpos preferidos tienen alta afinidad para hlL-13 y neutralizan la actividad hlL-13 in vitro e in vivo. Un anticuerpo de la presente invención puede ser un anticuerpo de longitud total o una parte de enlace de antígeno el mismo. También se proporciona un método para utilizar los anticuerpos de la presente invención. Los anticuerpos o partes de anticuerpo de la presente invención son útiles para detectar hlL-13 o para inhibir la actividad de hlL-13, por ejemplo en un sujeto humano que padece de un trastorno en el cual la actividad de hTL-13 es perjudicial.
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.019 seconds)
